HealthEquity, Inc. (NASDAQ:HQY) Receives $103.83 Average Price Target from Brokerages

HealthEquity, Inc. (NASDAQ:HQY) has received an average recommendation of “Buy” from the twelve ratings firms that are presently covering the company, Marketbeat reports. Twelve research analysts have rated the stock with a buy rating. The average 12 month target price among brokers that have covered the stock in the last year is $103.83.

A number of research firms have recently issued reports on HQY. Barrington Research reiterated an “outperform” rating and set a $105.00 price target on shares of HealthEquity in a research report on Friday, September 20th. Deutsche Bank Aktiengesellschaft lifted their price target on shares of HealthEquity from $102.00 to $103.00 and gave the company a “buy” rating in a research report on Wednesday, September 4th. Bank of America cut their price objective on HealthEquity from $105.00 to $100.00 and set a “buy” rating for the company in a research report on Wednesday, September 4th. JMP Securities restated a “market outperform” rating and set a $105.00 price objective on shares of HealthEquity in a research report on Wednesday, September 4th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $92.00 price objective on shares of HealthEquity in a research report on Wednesday, September 4th.

HealthEquity Price Performance

HQY stock opened at $88.07 on Tuesday. The firm has a 50 day moving average of $80.31 and a 200-day moving average of $79.75. HealthEquity has a 12-month low of $61.81 and a 12-month high of $89.23. The company has a current ratio of 4.10, a quick ratio of 4.10 and a debt-to-equity ratio of 0.51. The company has a market cap of $7.69 billion, a price-to-earnings ratio of 73.39, a PEG ratio of 1.37 and a beta of 0.52.

HealthEquity (NASDAQ:HQY) last posted its quarterly earnings results on Tuesday, September 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.50 by $0.16. HealthEquity had a net margin of 9.61% and a return on equity of 9.01%. The company had revenue of $299.93 million during the quarter, compared to the consensus estimate of $284.48 million. As a group, equities analysts expect that HealthEquity will post 2.27 EPS for the current fiscal year.

Insider Buying and Selling at HealthEquity

In other news, Director Frank Corvino sold 1,247 shares of the business’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $80.26, for a total transaction of $100,084.22. Following the completion of the sale, the director now directly owns 4,823 shares of the company’s stock, valued at $387,093.98. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, Director Frank Corvino sold 1,247 shares of the company’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $80.26, for a total transaction of $100,084.22. Following the completion of the sale, the director now directly owns 4,823 shares of the company’s stock, valued at approximately $387,093.98. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Robert W. Selander sold 8,250 shares of the company’s stock in a transaction on Wednesday, October 9th. The stock was sold at an average price of $82.98, for a total transaction of $684,585.00. Following the sale, the director now directly owns 54,719 shares of the company’s stock, valued at approximately $4,540,582.62. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On HealthEquity

Institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in shares of HealthEquity by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 8,768,632 shares of the company’s stock valued at $715,783,000 after purchasing an additional 149,133 shares in the last quarter. Diversify Advisory Services LLC acquired a new position in shares of HealthEquity during the first quarter valued at $7,828,000. Vaughan Nelson Investment Management L.P. acquired a new position in shares of HealthEquity during the first quarter valued at $49,443,000. Lisanti Capital Growth LLC acquired a new stake in HealthEquity in the first quarter worth about $4,701,000. Finally, Sei Investments Co. lifted its holdings in HealthEquity by 2.3% in the first quarter. Sei Investments Co. now owns 570,051 shares of the company’s stock worth $46,533,000 after purchasing an additional 12,958 shares during the period. Institutional investors and hedge funds own 99.55% of the company’s stock.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.